Processing

Please wait...

Settings

Settings

Goto Application

1. WO2013132317 - PEPTIDOMIMETIC COMPOUNDS AS IMMUNOMODULATORS

Publication Number WO/2013/132317
Publication Date 12.09.2013
International Application No. PCT/IB2013/000493
International Filing Date 04.03.2013
IPC
C07K 5/02 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
5Peptides having up to four amino acids in a fully defined sequence; Derivatives thereof
02containing at least one abnormal peptide link
CPC
A61K 31/16
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
16Amides, e.g. hydroxamic acids
A61K 31/197
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
19Carboxylic acids, e.g. valproic acid
195having an amino group
197the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
A61K 31/222
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
21Esters, e.g. nitroglycerine, selenocyanates
215of carboxylic acids
22of acyclic acids, e.g. pravastatin
222with compounds having aromatic groups, e.g. dipivefrine, ibopamine
A61K 31/405
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
40having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
403condensed with carbocyclic rings, e.g. carbazole
404Indoles, e.g. pindolol
405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
Applicants
  • AURIGENE DISCOVERY TECHNOLOGIES LIMITED [IN]/[IN]
Inventors
  • SASIKUMAR, Pottayil Govindan Nair
  • RAMACHANDRA, Muralidhara
  • NAREMADDEPALLI SEETHARAMAIAH SETTY, Sudarshan
Priority Data
854/CHE/201207.03.2012IN
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) PEPTIDOMIMETIC COMPOUNDS AS IMMUNOMODULATORS
(FR) COMPOSÉS PEPTIDOMIMÉTIQUES UTILISÉS COMME IMMUNOMODULATEURS
Abstract
(EN) The present invention relates to novel peptidomimetic compounds as therapeutic agents capable of inhibiting the programmed cell death 1 (PD1) signalling pathway. The invention also relates to derivatives of the therapeutic agents. The invention also encompasses the use of the said therapeutic agents and derivatives for treatment of disorders via immunopotentiation comprising inhibition of immunosuppressive signal induced due to PD-1, PD-L1, or PD-L2 and therapies using them.
(FR) La présente invention concerne de nouveaux composés peptidomimétiques utilisés comme agents thérapeutiques capables d'inhiber la voie de signalisation de la mort cellulaire programmée 1 (PD1). L'invention concerne également des dérivés desdits agents thérapeutiques. L'invention concerne aussi l'utilisation desdits agents thérapeutiques et dérivés pour le traitement de troubles par immunopotentialisation comprenant l'inhibition du signal immunosuppresseur induit par PD-1, PD-L1 ou PD-L2, ainsi que des thérapies les utilisant.
Related patent documents
Latest bibliographic data on file with the International Bureau